## Drug Summary
Rosiglitazone, marketed under various brand names including Avandia, is an anti-diabetic medication belonging to the thiazolidinedione class, primarily indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise. It functions by acting as a potent and selective agonist at peroxisome proliferator-activated receptor gamma (PPARγ), a receptor crucial for regulating the transcription of genes involved in glucose metabolism. The drug enhances tissue sensitivity to insulin by affecting adipose tissue, skeletal muscle, and liver. Rosiglitazone is well-absorbed with an absolute bioavailability of 99% and reaches peak plasma concentrations about 1 hour post-dose. It is extensively metabolized in the liver primarily by CYP2C8 and, to a lesser extent, CYP2C9, forming inactive metabolites.

## Drug Targets, Enzymes, Transporters, and Carriers
Rosiglitazone primarily targets PPARγ (peroxisome proliferator-activated receptor gamma) to exert its anti-diabetic effects. Additionally, interactions are noted with other nuclear receptors including PPARα and PPARδ, as well as various forms of retinoic acid receptors (RXRα, RXRβ, RXRγ). The drug's metabolism is mediated mainly by CYP2C8, with some contribution from CYP2C9 and other cytochromes like CYP1A2, CYP2D6, CYP3A4, CYP2B6, and CYP2E1. Key transporters involved include SLCO1B1, ABCB11, and SLC10A1. Rosiglitazone also interacts with serum albumin (ALB) as a carrier protein.

## Pharmacogenetics
Pharmacogenetically, the impact of rosiglitazone is significantly modulated by genetic variations. Variants in CYP2C8 can influence the metabolism and therefore the efficacy and safety of rosiglitazone. For example, carriers of CYP2C8*3, a variant allele with reduced enzymatic activity, might experience altered drug levels and potentially different therapeutic outcomes. Additionally, due to its mode of action, genetic variations in the PPARγ gene itself could impact the individual's response to rosiglitazone. Patients with different PPARγ polymorphisms might show variations in drug efficacy and risk of side effects. It's important to consider these genetic factors when prescribing rosiglitazone, potentially using pharmacogenetic testing to guide personalized treatment approaches. However, the exact clinical significance of most polymorphisms remains to be fully established in large-scale, multi-ethnic population studies.